In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications.
The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize biomarker assessment and refine precision medicine efforts in Gilead's oncology portfolio.
Next, we'll examine how integrating AI-driven tissue intelligence into Gilead's antibody-drug conjugate programs could influence its oncology-focused investment narrative.
Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
To own Gilead, you generally need to believe its HIV cash flows can fund a credible pivot into oncology, especially antibody drug conjugates like Trodelvy. The Nucleai collaboration looks incrementally positive for that story, but it does not change that the key near term catalyst is regulatory and commercial progress for Trodelvy in first line breast cancer, while a major risk remains execution on oncology and cell therapy returns after Gilead's recent net losses.
Among recent announcements, the extended collaboration with Arcus Biosciences in April 2026 is particularly relevant here, as it also leans into oncology and precision medicine. Taken together with the Nucleai partnership, it underlines how much of Gilead's medium term upside now rests on converting a growing network of oncology alliances into meaningful, approved products that can lessen its dependence on HIV revenue over time.
Yet while these partnerships may look promising, investors should be aware that...
Read the full narrative on Gilead Sciences (it's free!)
Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.
Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 7% upside to its current price.
Some analysts were already far more optimistic, assuming revenue could reach about US$38,100,000,000 by 2029, but this new AI driven ADC work might either strengthen or challenge those views as you weigh how dependent that upside is on Trodelvy's success.
Explore 5 other fair value estimates on Gilead Sciences - why the stock might be worth 13% less than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your Gilead Sciences research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GILD.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]